Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20110 + bevacizumab + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Hansoh BioMedical R&D Company
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HS-20110 + bevacizumab + 5-fluorouracil + leucovorin is an investigational combination therapy developed by Hansoh BioMedical R&D Company for the treatment of advanced colorectal cancer. The regimen consists of HS-20110, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2), combined with the anti-angiogenic monoclonal antibody bevacizumab and the chemotherapy doublet of 5-fluorouracil (5-FU) and leucovorin. HS-20110 is designed to bind to CLDN18.2-expressing tumor cells, potentially mediating anti-tumor effects through antibody-dependent cellular cytotoxicity (ADCC). Bevacizumab targets vascular endothelial growth factor A (VEGF-A) to inhibit tumor neovascularization, while 5-FU and leucovorin act as antimetabolites to disrupt DNA synthesis. This combination is specifically being evaluated in Phase Ib/II clinical trials for patients with advanced colorectal cancer that is non-MSI-H and BRAF V600E wild-type.
- Brand names
- Adrucil
- Other names
- 5-FUfolinic acidcalcium folinatefluorouracilHS20110HS-20110HS 20110
02
Targets
TS (Thymidylate synthase)CDH17 (Cadherin-17)TOP (DNA topoisomerases)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on HS-20110 + bevacizumab + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20110 + bevacizumab + 5-fluorouracil + leucovorin.